For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Haisu Yi, Qian Wang, Jiankai Deng, Hengchun Li, Yingkun Zhang, Zhilong Chen, Tianxin Ji, Wenming Liu, Xuehua Zheng, Qinghua Ma, Xinxin Sun, Yudi Zhang, Xuegao Yu, Mengzhang He, Ling Chen, Ying Feng. Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China [J].VIROLOGICA SINICA, 2022, 37(5) : 716-723.  http://dx.doi.org/10.1016/j.virs.2022.06.006

Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China

  • Human adenoviruses type 26 (HAdV26) and type 35 (HAdV35) have increasingly become the choice of adenovirus vectors for vaccine application. However, the population pre-existing immunity to these two adenoviruses in China, which may reduce vaccine efficacy, remains largely unknown. Here, we established micro-neutralizing (MN) assays to investigate the seroprevalence of neutralizing antibodies (nAbs) against HAdV26 and HAdV35 in the general population of Guangdong and Shandong provinces, China. A total of 1184 serum samples were collected, 47.0% and 15.8% of which showed HAdV26 and HAdV35 nAb activity, respectively. HAdV26-seropositive individuals tended to have more moderate nAbs titers (201–1000), while HAdV35-seropositive individuals appeared to have more low nAbs titers (72–200). The seropositive rates of HAdV26 and HAdV35 in individuals younger than 20 years old were very low. The seropositive rates of HAdV26 increased with age before 70 years old and decreased thereafter, while HAdV35 seropositive rates did not show similar characteristics. Notably, the seropositive rates and nAb levels of both HAdV26 and HAdV35 were higher in Guangdong Province than in Shandong Province, but did not exert significant differences between males and females. The seroprevalence between HAdV26 and HAdV35 showed little correlation, and no significant cross-neutralizing activity was detected. These results clarified the characteristics of the herd immunity against HAdV26 and HAdV35, and provided information for the rational development and application of HAdV26 and HAdV35 as vaccine vectors in China.

  • 加载中
  • 10.1016j.virs.2022.06.006-ESM.docx
    1. Abbink, P., Lemckert, A.A., Ewald, B.A., Lynch, D.M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A.R., O'Brien, K.L., Carville, A., Mansfield, K.G., Goudsmit, J., Havenga, M.J., Barouch, D.H., 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups b and d. J. Virol. 81, 4654-4663.

    2. Alderson, J., Batchelor, V., O'Hanlon, M., Cifuentes, L., Richter, F.C., Kopycinski, J., Oxford-Cardiff, C.-L.C., 2021. Overview of approved and upcoming vaccines for sarscov-2:a living review. Oxf Open Immunol 2, iqab010.

    3. Aste-Amezaga, M., Bett, A.J., Wang, F., Casimiro, D.R., Antonello, J.M., Patel, D.K., Dell, E.C., Franlin, L.L., Dougherty, N.M., Bennett, P.S., Perry, H.C., Davies, M.E., Shiver, J.W., Keller, P.M., Yeager, M.D., 2004. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene:application in epidemiologic studies and in the design of adenovector vaccines. Hum. Gene Ther. 15, 293-304.

    4. Baden, L.R., Walsh, S.R., Seaman, M.S., Tucker, R.P., Krause, K.H., Patel, A., Johnson, J.A., Kleinjan, J., Yanosick, K.E., Perry, J., Zablowsky, E., Abbink, P., Peter, L., Iampietro, M.J., Cheung, A., Pau, M.G., Weijtens, M., Goudsmit, J., Swann, E., Wolff, M., Loblein, H., Dolin, R., Barouch, D.H., 2013. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 hiv-1 env vaccine (ipcavd 001). J. Infect. Dis. 207, 240-247.

    5. Baden, L.R., Liu, J., Li, H., Johnson, J.A., Walsh, S.R., Kleinjan, J.A., Engelson, B.A., Peter, L., Abbink, P., Milner Jr., D.A., Golden, K.L., Viani, K.L., Stachler, M.D., Chen, B.J., Pau, M.G., Weijtens, M., Carey, B.R., Miller, C.A., Swann, E.M., Wolff, M., Loblein, H., Seaman, M.S., Dolin, R., Barouch, D.H., 2015. Induction of hiv-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 hiv-1 vaccination of humans. J. Infect. Dis. 211, 518-528.

    6. Barouch, D.H., Liu, J., Peter, L., Abbink, P., Iampietro, M.J., Cheung, A., Alter, G., Chung, A., Dugast, A.S., Frahm, N., McElrath, M.J., Wenschuh, H., Reimer, U., Seaman, M.S., Pau, M.G., Weijtens, M., Goudsmit, J., Walsh, S.R., Dolin, R., Baden, L.R., 2013. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 hiv-1 env vaccine in healthy adults(ipcavd 001). J. Infect. Dis. 207, 248-256.

    7. Barouch, D.H., Kik, S.V., Weverling, G.J., Dilan, R., King, S.L., Maxfield, L.F., Clark, S., Ng 'ang' a, D., Brandariz, K.L., Abbink, P., Sinangil, F., de Bruyn, G., Gray, G.E., Roux, S., Bekker, L.G., Dilraj, A., Kibuuka, H., Robb, M.L., Michael, N.L., Anzala, O., Amornkul, P.N., Gilmour, J., Hural, J., Buchbinder, S.P., Seaman, M.S., Dolin, R., Baden, L.R., Carville, A., Mansfield, K.G., Pau, M.G., Goudsmit, J., 2011. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29, 5203-5209.

    8. Berciaud, S., Rayne, F., Kassab, S., Jubert, C., Faure-Della Corte, M., Salin, F., Wodrich, H., Lafon, M.E., Typadeno Study, M., 2012. Adenovirus infections in bordeaux university hospital 2008-2010:clinical and virological features. J. Clin. Virol. 54, 302-307.

    9. Bradley, R.R., Lynch, D.M., Iampietro, M.J., Borducchi, E.N., Barouch, D.H., 2012. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol. 86, 625-629.

    10. Creech, C.B., Dekker, C.L., Ho, D., Phillips, S., Mackey, S., Murray-Krezan, C., Grazia Pau, M., Hendriks, J., Brown, V., Dally, L.G., Versteege, I., Edwards, K.M., 2013. Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum. Vaccines Immunother. 9, 2548-2557.

    11. Crenshaw, B.J., Jones, L.B., Bell, C.R., Kumar, S., Matthews, Q.L., 2019. Perspective on adenoviruses:epidemiology, pathogenicity, and gene therapy. Biomedicines 7, 61.

    12. Geisbert, T.W., Bailey, M., Hensley, L., Asiedu, C., Geisbert, J., Stanley, D., Honko, A., Johnson, J., Mulangu, S., Pau, M.G., Custers, J., Vellinga, J., Hendriks, J., Jahrling, P., Roederer, M., Goudsmit, J., Koup, R., Sullivan, N.J., 2011. Recombinant adenovirus serotype 26 (ad26) and ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 85, 4222-4233.

    13. Ghebremedhin, B., 2014. Human adenovirus:viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp) 4, 26-33.

    14. Goldstein, N., Bockstal, V., Bart, S., Luhn, K., Robinson, C., Gaddah, A., Callendret, B., Douoguih, M., 2020. Safety and immunogenicity of heterologous and homologous two dose regimens of ad26- and mva-vectored ebola vaccines:a randomized, controlled phase 1 study. J Infect Dis. Jiaa 586.

    15. Greber, U.F., 2020. Adenoviruses-infection, pathogenesis and therapy. FEBS Lett. 594, 1818-1827.

    16. Huang, Y., Wang, C., Ma, F., Guo, Q., Yao, L., Chen, A., Luo, X., Zheng, L., 2021. Human adenoviruses in paediatric patients with respiratory tract infections in beijing, China. Virol. J. 18, 191.

    17. Ismail, A.M., Cui, T., Dommaraju, K., Singh, G., Dehghan, S., Seto, J., Shrivastava, S., Fedorova, N.B., Gupta, N., Stockwell, T.B., Halpin, R., Madupu, R., Heim, A., Kajon, A.E., Romanowski, E.G., Kowalski, R.P., Malathi, J., Therese, K.L., Madhavan, H.N., Zhang, Q., Ferreyra, L.J., Jones, M.S., Rajaiya, J., Dyer, D.W., Chodosh, J., Seto, D., 2018. Genomic analysis of a large set of currently-and historically-important human adenovirus pathogens. Emerg. Microb. Infect. 7, 10.

    18. Kajon, A.E., Lamson, D.M., Bair, C.R., Lu, X., Landry, M.L., Menegus, M., Erdman, D.D., St George, K., 2018. Adenovirus type 4 respiratory infections among civilian adults, northeastern United States, 2011-2015(1). Emerg. Infect. Dis. 24, 201-209.

    19. Keefer, M.C., Gilmour, J., Hayes, P., Gill, D., Kopycinski, J., Cheeseman, H., CashinCox, M., Naarding, M., Clark, L., Fernandez, N., Bunce, C.A., Hay, C.M., Welsh, S., Komaroff, W., Hachaambwa, L., Tarragona-Fiol, T., Sayeed, E., Zachariah, D., Ackland, J., Loughran, K., Barin, B., Cormier, E., Cox, J.H., Fast, P., Excler, J.L., 2012. A phase i double blind, placebo-controlled, randomized study of a multigenic hiv-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 7, e41936.

    20. Kuriyama, S., Tominaga, K., Kikukawa, M., Nakatani, T., Tsujinoue, H., Yamazaki, M., Nagao, S., Toyokawa, Y., Mitoro, A., Fukui, H., 1998. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res. 18, 2345-2351.

    21. Logunov, D.Y., Dolzhikova, I.V., Zubkova, O.V., Tukhvatullin, A.I., Shcheblyakov, D.V., Dzharullaeva, A.S., Grousova, D.M., Erokhova, A.S., Kovyrshina, A.V., Botikov, A.G., Izhaeva, F.M., Popova, O., Ozharovskaya, T.A., Esmagambetov, I.B., Favorskaya, I.A., Zrelkin, D.I., Voronina, D.V., Shcherbinin, D.N., Semikhin, A.S., Simakova, Y.V., Tokarskaya, E.A., Lubenets, N.L., Egorova, D.A., Shmarov, M.M., Nikitenko, N.A., Morozova, L.F., Smolyarchuk, E.A., Kryukov, E.V., Babira, V.F., Borisevich, S.V., Naroditsky, B.S., Gintsburg, A.L., 2020a. Safety and immunogenicity of an rad26 and rad5 vector-based heterologous prime-boost covid-19 vaccine in two formulations:two open, non-randomised phase 1/2 studies from Russia. Lancet 396, 887-897.

    22. Logunov, D.Y., Dolzhikova, I.V., Zubkova, O.V., Tukhvatulin, A.I., Shcheblyakov, D.V., Dzharullaeva, A.S., Grousova, D.M., Erokhova, A.S., Kovyrshina, A.V., Botikov, A.G., Izhaeva, F.M., Popova, O., Ozharovskaya, T.A., Esmagambetov, I.B., Favorskaya, I.A., Zrelkin, D.I., Voronina, D.V., Shcherbinin, D.N., Semikhin, A.S., Simakova, Y.V., Tokarskaya, E.A., Lubenets, N.L., Egorova, D.A., Shmarov, M.M., Nikitenko, N.A., Morozova, L.F., Smolyarchuk, E.A., Kryukov, E.V., Babira, V.F., Borisevich, S.V., Naroditsky, B.S., Gintsburg, A.L., 2020b. Safety and immunogenicity of an rad26 and rad5 vector-based heterologous prime-boost covid-19 vaccine in two formulations:two open, non-randomised phase 1/2 studies from Russia. Lancet 396, 887-897.

    23. Lynch 3rd, J.P., Kajon, A.E., 2016. Adenovirus:epidemiology, global spread of novel serotypes, and advances in treatment and prevention. Semin. Respir. Crit. Care Med. 37, 586-602.

    24. Madisch, I., Harste, G., Pommer, H., Heim, A., 2005. Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. J. Virol. 79, 15265-15276.

    25. Mendonca, S.A., Lorincz, R., Boucher, P., Curiel, D.T., 2021. Adenoviral vector vaccine platforms in the sars-cov-2 pandemic. NPJ Vaccines 6, 97.

    26. Mennechet, F.J.D., Paris, O., Ouoba, A.R., Salazar Arenas, S., Sirima, S.B., Takoudjou Dzomo, G.R., Diarra, A., Traore, I.T., Kania, D., Eichholz, K., Weaver, E.A., Tuaillon, E., Kremer, E.J., 2019. A review of 65 years of human adenovirus seroprevalence. Expert Rev. Vaccines 18, 597-613.

    27. Omosa-Manyonyi, G., Mpendo, J., Ruzagira, E., Kilembe, W., Chomba, E., Roman, F., Bourguignon, P., Koutsoukos, M., Collard, A., Voss, G., Laufer, D., Stevens, G., Hayes, P., Clark, L., Cormier, E., Dally, L., Barin, B., Ackland, J., Syvertsen, K., Zachariah, D., Anas, K., Sayeed, E., Lombardo, A., Gilmour, J., Cox, J., Fast, P., Priddy, F., 2015. A phase i double blind, placebo-controlled, randomized study of the safety and immunogenicity of an adjuvanted hiv-1 gag-pol-nef fusion protein and adenovirus 35 gag-rt-int-nef vaccine in healthy hiv-uninfected african adults. PLoS One 10, e0125954.

    28. Otto, W.R., Behrens, E.M., Teachey, D.T., Lamson, D.M., Barrett, D.M., Bassiri, H., Lambert, M.P., Mount, S., Petrosa, W.L., Romberg, N., Sullivan, K.E., Topjian, A.A., Fisher, B.T., Kajon, A.E., 2021. Human adenovirus 7-associated hemophagocytic lymphohistiocytosis-like illness:clinical and virological characteristics in a cluster of five pediatric cases. Clin. Infect. Dis. 73, e1532-e1538.

    29. Ouédraogo, A., Tiono, A.B., Kargougou, D., Yaro, J.B., Ouédraogo, E., Kaboré, Y., Kangoye, D., Bougouma, E.C., Gansane, A., Henri, N., Diarra, A., Sanon, S., Soulama, I., Konate, A.T., Watson, N.L., Brown, V., Hendriks, J., Pau, M.G., Versteege, I., Wiesken, E., Sadoff, J., Nebie, I., Sirima, S.B., 2013. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in burkinabe healthy adults 18 to 45 years of age. PLoS One 8, e78679.

    30. Pscheidt, V.M., Gregianini, T.S., Martins, L.G., Veiga, A., 2021. Epidemiology of human adenovirus associated with respiratory infection in southern Brazil. Rev. Med. Virol. 31, e2189.

    31. Roberts, D.M., Nanda, A., Havenga, M.J., Abbink, P., Lynch, D.M., Ewald, B.A., Liu, J., Thorner, A.R., Swanson, P.E., Gorgone, D.A., Lifton, M.A., Lemckert, A.A., Holterman, L., Chen, B., Dilraj, A., Carville, A., Mansfield, K.G., Goudsmit, J., Barouch, D.H., 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent preexisting anti-vector immunity. Nature 441, 239-243.

    32. Robinson, C.M., Singh, G., Lee, J.Y., Dehghan, S., Rajaiya, J., Liu, E.B., Yousuf, M.A., Betensky, R.A., Jones, M.S., Dyer, D.W., Seto, D., Chodosh, J., 2013. Molecular evolution of human adenoviruses. Sci. Rep. 3, 1812.

    33. Sadoff, J., De Paepe, E., DeVincenzo, J., Gymnopoulou, E., Menten, J., Murray, B., Bastian, A.R., Vandebosch, A., Haazen, W., Noulin, N., Comeaux, C., Heijnen, E., Eze, K., Gilbert, A., Lambkin-Williams, R., Schuitemaker, H., Callendret, B., 2021a. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of ad26.Rsv.Pref in a human challenge study. J Infect Dis. Jiab:003.

    34. Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K.L., Robb, M.L., Treanor, J., Barouch, D.H., Stoddard, J., Ryser, M.F., Marovich, M.A., Neuzil, K.M., Corey, L., Cauwenberghs, N., Tanner, T., Hardt, K., Ruiz-Guiñazú, J., Le Gars, M., Schuitemaker, H., Van Hoof, J., Struyf, F., Douoguih, M., 2021b. Safety and efficacy of single-dose ad26.Cov2.S vaccine against covid-19. N. Engl. J. Med. 384, 2187-2201.

    35. Salisch, N.C., Stephenson, K.E., Williams, K., Cox, F., van der Fits, L., Heerwegh, D., Truyers, C., Habets, M.N., Kanjilal, D.G., Larocca, R.A., Abbink, P., Liu, J., Peter, L., Fierro, C., De La Barrera, R.A., Modjarrad, K., Zahn, R.C., Hendriks, J., Cahill, C.P., Leyssen, M., Douoguih, M., van Hoof, J., Schuitemaker, H., Barouch, D.H., 2021. A double-blind, randomized, placebo-controlled phase 1 study of ad26.Zikv.001, an ad26-vectored anti-zika virus vaccine. Ann. Intern. Med. 174, 585-594.

    36. Schmitz, H., Wigand, R., Heinrich, W., 1983. Worldwide epidemiology of human adenovirus infections. Am. J. Epidemiol. 117, 455-466.

    37. Skowronski, D.M., De Serres, G., 2021. Safety and efficacy of the bnt162b2 mrna covid-19 vaccine. N. Engl. J. Med. 384, 1576-1577.

    38. Sun, C., Zhang, Y., Feng, L., Pan, W., Zhang, M., Hong, Z., Ma, X., Chen, X., Chen, L., 2011. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and aids patients in guangzhou, southern China. Vaccine 29, 3837-3841.

    39. Tatsis, N., Ertl, H.C., 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10, 616-629.

    40. Tian, X., Jiang, Z., Ma, Q., Liu, Q., Lu, X., Liu, W., Liao, X., Zhou, R., Su, X., Luo, Q., 2016. Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. J. Thorac. Dis. 8, 803-812.

    41. Vergnes, J.N., 2021. Safety and efficacy of the bnt162b2 mrna covid-19 vaccine. N. Engl. J. Med. 384, 1577.

    42. Wadell, G., Cooney, M.K., da Costa Linhares, A., de Silva, L., Kennett, M.L., Kono, R., GuiFang, R., Lindman, K., Nascimento, J.P., Schoub, B.D., et al., 1985. Molecular epidemiology of adenoviruses:global distribution of adenovirus 7 genome types. J. Clin. Microbiol. 21, 403-408.

    43. Wang, X., Xing, M., Zhang, C., Yang, Y., Chi, Y., Tang, X., Zhang, H., Xiong, S., Yu, L., Zhou, D., 2014. Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg. Microb. Infect. 3, e30.

    44. Westerberg, S., Hagbom, M., Rajan, A., Loitto, V., Persson, B.D., Allard, A., Nordgren, J., Sharma, S., Magnusson, K.E., Arnberg, N., Svensson, L., 2018. Interaction of human enterochromaffin cells with human enteric adenovirus 41 leads to serotonin release and subsequent activation of enteric glia cells. J. Virol. 92, e00026, 18.

    45. Widjojoatmodjo, M.N., Bogaert, L., Meek, B., Zahn, R., Vellinga, J., Custers, J., Serroyen, J., Radošević, K., Schuitemaker, H., 2015. Recombinant low-seroprevalent adenoviral vectors ad26 and ad35 expressing the respiratory syncytial virus (rsv) fusion protein induce protective immunity against rsv infection in cotton rats. Vaccine 33, 5406-5414.

    46. Xiang, Z., Li, Y., Cun, A., Yang, W., Ellenberg, S., Switzer, W.M., Kalish, M.L., Ertl, H.C., 2006. Chimpanzee adenovirus antibodies in humans, sub-saharan africa. Emerg. Infect. Dis. 12, 1596-1599.

    47. Xin, K.Q., Jounai, N., Someya, K., Honma, K., Mizuguchi, H., Naganawa, S., Kitamura, K., Hayakawa, T., Saha, S., Takeshita, F., Okuda, K., Honda, M., Klinman, D.M., Okuda, K., 2005. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against hiv. Gene Ther. 12, 1769-1777.

    48. Ye, X., Xiao, L., Zheng, X., Wang, J., Shu, T., Feng, Y., Liu, X., Su, W., Wang, Q., Li, C., Chen, L., Feng, L., 2018. Seroprevalence of neutralizing antibodies to human adenovirus type 4 and 7 in healthy populations from southern China. Front. Microbiol. 9, 3040.

    49. Yu, B., Zhou, Y., Wu, H., Wang, Z., Zhan, Y., Feng, X., Geng, R., Wu, Y., Kong, W., Yu, X., 2012. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J. Med. Virol. 84, 1408-1414.

    50. Zhang, C., Zhou, D., 2016. Adenoviral vector-based strategies against infectious disease and cancer. Hum. Vaccines Immunother. 12, 2064-2074.

    51. Zhang, S., Huang, W., Zhou, X., Zhao, Q., Wang, Q., Jia, B., 2013. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J. Med. Virol. 85, 1077-1084.

    52. Zheng, X., Rong, X., Feng, Y., Sun, X., Li, L., Wang, Q., Wang, M., Liu, W., Li, C., Yang, Y., Zhou, R., Lu, J., Feng, L., Chen, L., 2017. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in southern China. Emerg. Microb. Infect. 6, e43.

    53. Zhu, F.C., Guan, X.H., Li, Y.H., Huang, J.Y., Jiang, T., Hou, L.H., Li, J.X., Yang, B.F., Wang, L., Wang, W.J., Wu, S.P., Wang, Z., Wu, X.H., Xu, J.J., Zhang, Z., Jia, S.Y., Wang, B.S., Hu, Y., Liu, J.J., Zhang, J., Qian, X.A., Li, Q., Pan, H.X., Jiang, H.D., Deng, P., Gou, J.B., Wang, X.W., Wang, X.H., Chen, W., 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored covid-19 vaccine in healthy adults aged 18 years or older:a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479-488.

  • 加载中

Article Metrics

Article views(348) PDF downloads(3) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China

      Corresponding author: Ling Chen, chen_ling@gibh.ac.cn
      Corresponding author: Ying Feng, feng_ying@gibh.ac.cn
    • a State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China;
    • b Department of Laboratory Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China;
    • c Center for Infection and Immunity, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China;
    • d Clinical Laboratory, Pingyi Hospital of Chinese Medicine, Linyi, 273399, China;
    • e Xiamen Institutes of Respiratory Health, Xiamen, 361013, China;
    • f Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China;
    • g. University of Chinese Academy of Science, Beijing, 100049, China;
    • h. Guangzhou Laboratory & Bioland Laboratory, Guangzhou, 510320, China

    Abstract: Human adenoviruses type 26 (HAdV26) and type 35 (HAdV35) have increasingly become the choice of adenovirus vectors for vaccine application. However, the population pre-existing immunity to these two adenoviruses in China, which may reduce vaccine efficacy, remains largely unknown. Here, we established micro-neutralizing (MN) assays to investigate the seroprevalence of neutralizing antibodies (nAbs) against HAdV26 and HAdV35 in the general population of Guangdong and Shandong provinces, China. A total of 1184 serum samples were collected, 47.0% and 15.8% of which showed HAdV26 and HAdV35 nAb activity, respectively. HAdV26-seropositive individuals tended to have more moderate nAbs titers (201–1000), while HAdV35-seropositive individuals appeared to have more low nAbs titers (72–200). The seropositive rates of HAdV26 and HAdV35 in individuals younger than 20 years old were very low. The seropositive rates of HAdV26 increased with age before 70 years old and decreased thereafter, while HAdV35 seropositive rates did not show similar characteristics. Notably, the seropositive rates and nAb levels of both HAdV26 and HAdV35 were higher in Guangdong Province than in Shandong Province, but did not exert significant differences between males and females. The seroprevalence between HAdV26 and HAdV35 showed little correlation, and no significant cross-neutralizing activity was detected. These results clarified the characteristics of the herd immunity against HAdV26 and HAdV35, and provided information for the rational development and application of HAdV26 and HAdV35 as vaccine vectors in China.

    Reference (53) Relative (20)

    目录

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return